Achondroplasia Therapeutic Landscape Discussed by GMD in Its In-demand Report Available at MarketPublishers.com
04 May 2017 • by Natalie Aster
LONDON – Achondroplasia is a born growth disorder that brings about disproportionate dwarfism (short stature as an adult). This is caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. Symptoms comprise decreased tonus, apneustic breath, hydrocephaly, short legs and arms, disproportionately large head in comparison with the body and kyphosis.
Achondroplasia occurs in around 1 in 25,000 live births, equally prevalent in females and males.
There is no cure or particular treatment for achondroplasia. Growth hormones can be used to enhance the growth rates of some children. Nevertheless, their effects on height in the long-term haven’t been detected and are deemed to be modest in a best-case scenario.
Surgery is also a treatment option in a number of cases to enhance leg length by up to 30 cm, impede spinal compression, or improve bow legs condition.
The majority of people with achondroplasia have a normal length of life. Nevertheless, there’s a slightly increased probability of dying in the first year of life. There is also a high possibility of cardiac disease in later life.
In-demand research report “Achondroplasia - Pipeline Review, H1 2017” elaborated by GMD provides deep insights into the therapeutic universe of achondroplasia achondroplasia (musculoskeletal disorders) on a global level.
The report casts light on pipeline therapeutics for the disorder by firms and universities/research organisations. It casts light on the pipeline products by several phases of development. The study offers comprehensive profiling of the pipeline products, covering product descriptions, descriptive collaboration and licensing details, R&D activities, MoA, etc. The report reviews top companies engaged in the development of therapeutics including a listing of their key and minor projects. The study evaluates achondroplasia therapeutics based on MoA, drug target, molecule type and RoA. All dormant and discontinued pipeline projects are covered in the report. The research reviews up-to-the-minute news pertaining to pipeline therapeutics for the disorder.
More in-demand research reports by our partner can be found at GMD page.